NASDAQ:REPH - Recro Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.24 -0.12 (-1.44 %)
(As of 04/22/2019 04:00 PM ET)
Previous Close$8.36
Today's Range$8.17 - $8.42
52-Week Range$4.78 - $13.05
Volume189,458 shs
Average Volume385,274 shs
Market Capitalization$181.21 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.36
Recro Pharma, Inc., a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. The company also develops early-stage product candidates, which include Dex-IN, an intranasal formulation of dexmedetomidine for use in clinical sedation; and two novel neuromuscular blocking agents and a related proprietary chemical reversal agent. In addition, it provides formulation and development services to develop and manufacture pharmaceutical products using proprietary delivery technologies and know-how for commercial partners. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.35 million
Book Value($0.91) per share

Profitability

Net Income$-79,720,000.00
Net Margins-103.07%

Miscellaneous

Employees255
Market Cap$181.21 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) announced its earnings results on Tuesday, February, 19th. The specialty pharmaceutical company reported ($0.58) EPS for the quarter, topping the Zacks' consensus estimate of ($0.75) by $0.17. The specialty pharmaceutical company earned $17.78 million during the quarter, compared to analysts' expectations of $16.01 million. Recro Pharma had a negative return on equity of 472.58% and a negative net margin of 103.07%. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Recro Pharma.

What price target have analysts set for REPH?

4 brokerages have issued 12-month price objectives for Recro Pharma's shares. Their forecasts range from $7.50 to $15.00. On average, they anticipate Recro Pharma's stock price to reach $11.3750 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

News articles about REPH stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Recro Pharma earned a news impact score of 1.7 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the next several days.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 949,759 shares, an increase of 48.0% from the March 15th total of 641,599 shares. Based on an average daily volume of 805,028 shares, the short-interest ratio is currently 1.2 days. Approximately 5.4% of the company's shares are short sold. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.28%), Virtu Financial LLC (0.06%), Truvestments Capital LLC (0.03%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Recro Pharma stock include Healthcare Master Fun Broadfin, James E Flynn, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp and Stonepine Capital Management,. View Institutional Ownership Trends for Recro Pharma.

Which institutional investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. View Insider Buying and Selling for Recro Pharma.

Which institutional investors are buying Recro Pharma stock?

REPH stock was purchased by a variety of institutional investors in the last quarter, including Truvestments Capital LLC, Meeder Asset Management Inc. and Virtu Financial LLC. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $8.24.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $181.21 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.

What is Recro Pharma's official website?

The official website for Recro Pharma is http://www.recropharma.com.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  268 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  488
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/22/2019 by MarketBeat.com Staff

Featured Article: Net Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel